Stirling products to test growth promotors in sheep.
Wednesday, 30 June, 2004
Perth-based Stirling Products (ASX:STI) is preparing for the first animal trials of its ST810 growth promotion agent in sheep.
This trial will test the affect of ST810's -- a beta-2 agonist -- on tissue weight gain and carcass quality. In published scientific literature beta-agonists have been reported to increase lean meat in sheep from 15 to 35 per cent and reduce carcass fat from 25 to 45 per cent.
Because it is a pure 'single enantiomer' molecule, rather than a mix of right and left-handed enantiomers, STA-810 stimulates only beta-2 receptors. Current growth promotant products are both beta-1 and beta-2 agonists. Selectively stimulating beta-2 receptors may mean decreased side-effects, as beta-1 agonists are associated with increased heart rate.
The trial is scheduled to commence in early spring following trial protocol and animal ethics submissions.
Shares in Stirling were up 5 per cent to AUD$0.205.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
